摘要:
Two crystalline forms of pinocembrin of formula (I): α and β, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.
摘要:
Two crystalline forms of pinocembrin of formula (I): α and β, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.
摘要:
Inclusion complexes of pinocembrin with cyclodextrin or its derivatives and their preparation are provided. The inclusion complexes can be used to make drugs.
摘要:
Inclusion complexes of pinocembrin with cyclodextrin or its derivatives and their preparation are provided. The inclusion complexes can be used to make drugs.
摘要:
The present invention relates to a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, using a chiral primary amine or a chiral sulfinamide. The present invention also relates to a (R)-(+)-pinocembrin obtained by the method.
摘要:
The present invention relates to a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, using a chiral primary amine or a chiral sulfinamide. The present invention also relates to a (R)-(+)-pinocembrin obtained by the method.
摘要:
Use of a racemate of pinocembrin, a racemate of pinocembrin salt, a racemate of pinocembrin precursor or a racemate of pinocembrin hydrate in manufacture of a medicament for prophylaxis and treatment of stroke. Particularly, use of pinocembrin racemate in manufacture of a medicament for treatment of acute ischemic stroke.
摘要:
The method for power control in HSDPA includes Step A, the UE with the highest priority and having data to be transmitted is selected according to the algorithm, the channel resource is distributed to the UE, and the original power level is set. Step B, the transmission power is deduced when the channel quality meets the condition; Otherwise the CQI is checked, if the value of CQI is under the highest rate level, or the data is the re-transmitting data, the transmission power is increased, or the power is kept the same level. Step C, channel resource and the UE with the highest priority are checked, if there exist, then go to step B, otherwise the method is ended. So the redundant power can be used when several UEs are controlled at the same time, the efficiency and the throughput performance are improved, and the interface is reduced. The device for power controlling is given at the same time.
摘要:
An attribute presenter of object attributes from at least one object includes an attribute controller for determining which attributes to select; an attribute collector for collecting and normalizing the determined attributes from the at least one object; an attribute organizer for organizing the collected and normalized attributes for display; and an attribute viewer for displaying the organized object attributes. A method for presenting object attributes using an attribute presenter includes the steps of determining which object attributes to select using an attribute controller; collecting and normalizing the determined object attributes from at least one object using an attribute collector; organizing the collected and normalized object attributes for display by an attribute organizer; and displaying the organized object attributes by an attribute viewer.
摘要:
The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2′,3′,5′-tri-O-acetyl-N6-(3-hydroxyphenyl)adenosine. Using hypoxanthine nucleoside as starting material, the compound is prepared by acetylating with acetic anhydride, chlorinating with thionyl chloride, and being substituted with 3-hydroxy aniline. The invention also discloses the pharmaceutical composition comprising triacetyl-3-hydroxyphenyladenosine. The dosage forms of the said pharmaceutical composition include tablet, capsule, pill, injection, sustained release preparation, controlled release preparation or particulate delivery system. The medicament for treatment or precaution of hyperlipemia prepared by the compound of the invention has the advantages of significant hypolipidemic activity, less toxicity and adverse effect as well as slow metabolism in vivo.